NUZ — Neurizon Therapeutics Share News
0.000.00%
Last trade - 00:00- AU$62.62m
- AU$53.22m
Australia's PharmAust falls on discounted placement
Brief: Pharmaust Seeks Trading Halt
Brief: Pharmaust Says Reappointed Michael Thurn As Managing Director And CEO
Brief: PharmAust Receives Orphan Drug Designation From US FDA For Monepantel
Australia's PharmAust jumps on FDA's 'orphan' tag for neuron disease drug
Brief: Pharmaust Appoints Sergio Duchini As Non-Executive Chairman
Brief: Pharmaust Ltd Says Sam Wright Has Been Appointed Interim Chairman Of Pharmaust
Brief: Pharmaust Ltd Seeks Trading Halt
Brief: Pharmaust Ltd Says Chief Executive Officer Michael Thurn, Has Tendered His Resignation
Australia's PharmAust rises after approval to start study
Brief: Pharmaust Seeks Trading Halt
Brief: Pharmaust Files Positive Clinical Data With FDA To Support Orphan Drug Designation Request
Brief: Pharmaust Ltd Seeks Trading Halt
Brief: Pharmaust Says Successfully Completed A Pre-Ind Meeting With FDA
Australia's PharmAust rises on effective first patient dosing
Brief: Pharmaust Says FDA Provided Clear Feedback For ODD Approval
Australia's PharmAust hits over 3-yr high on partnering with MND specialist
Brief: Pharmaust Partners With Berry Consultants For Phase 2/3 MND Study
Australia's PharmAust hits 3-year high after FDA grants Pre-IND meeting